Cargando…
Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever
Q fever, caused by the intracellular pathogen Coxiella burnetii, is traditionally treated using tetracycline antibiotics, such as doxycycline. Doxycycline is often poorly tolerated, and antibiotic-resistant strains have been isolated. In this study, we have evaluated a panel of antibiotics (doxycycl...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522727/ https://www.ncbi.nlm.nih.gov/pubmed/34370577 http://dx.doi.org/10.1128/AAC.00673-21 |
_version_ | 1784585150008393728 |
---|---|
author | Clay, K. A. Hartley, M. G. Armstrong, S. Bewley, K. R. Godwin, K. Rayner, E. Vipond, J. Bailey, M. Atkins, T. P. Norville, I. H. |
author_facet | Clay, K. A. Hartley, M. G. Armstrong, S. Bewley, K. R. Godwin, K. Rayner, E. Vipond, J. Bailey, M. Atkins, T. P. Norville, I. H. |
author_sort | Clay, K. A. |
collection | PubMed |
description | Q fever, caused by the intracellular pathogen Coxiella burnetii, is traditionally treated using tetracycline antibiotics, such as doxycycline. Doxycycline is often poorly tolerated, and antibiotic-resistant strains have been isolated. In this study, we have evaluated a panel of antibiotics (doxycycline, ciprofloxacin, levofloxacin, and co-trimoxazole) against C. burnetii using in vitro methods (determination of MIC using liquid and solid media; efficacy assessment in a THP cell infection model) and in vivo methods (wax moth larvae and mouse models of infection). In addition, the schedule for antibiotic treatment has been evaluated, with therapy initiated at 24 h pre- or postchallenge. Both doxycycline and levofloxacin limited overt clinical signs during treatment in the AJ mouse model of aerosol infection, but further studies are required to investigate the possibility of disease relapse or incomplete bacterial clearance after the antibiotics are stopped. Levofloxacin was well tolerated and therefore warrants further investigation as an alternative to the current recommended treatment with doxycycline. |
format | Online Article Text |
id | pubmed-8522727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-85227272021-10-20 Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever Clay, K. A. Hartley, M. G. Armstrong, S. Bewley, K. R. Godwin, K. Rayner, E. Vipond, J. Bailey, M. Atkins, T. P. Norville, I. H. Antimicrob Agents Chemother Experimental Therapeutics Q fever, caused by the intracellular pathogen Coxiella burnetii, is traditionally treated using tetracycline antibiotics, such as doxycycline. Doxycycline is often poorly tolerated, and antibiotic-resistant strains have been isolated. In this study, we have evaluated a panel of antibiotics (doxycycline, ciprofloxacin, levofloxacin, and co-trimoxazole) against C. burnetii using in vitro methods (determination of MIC using liquid and solid media; efficacy assessment in a THP cell infection model) and in vivo methods (wax moth larvae and mouse models of infection). In addition, the schedule for antibiotic treatment has been evaluated, with therapy initiated at 24 h pre- or postchallenge. Both doxycycline and levofloxacin limited overt clinical signs during treatment in the AJ mouse model of aerosol infection, but further studies are required to investigate the possibility of disease relapse or incomplete bacterial clearance after the antibiotics are stopped. Levofloxacin was well tolerated and therefore warrants further investigation as an alternative to the current recommended treatment with doxycycline. American Society for Microbiology 2021-10-18 /pmc/articles/PMC8522727/ /pubmed/34370577 http://dx.doi.org/10.1128/AAC.00673-21 Text en © Crown copyright 2021. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Experimental Therapeutics Clay, K. A. Hartley, M. G. Armstrong, S. Bewley, K. R. Godwin, K. Rayner, E. Vipond, J. Bailey, M. Atkins, T. P. Norville, I. H. Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever |
title | Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever |
title_full | Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever |
title_fullStr | Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever |
title_full_unstemmed | Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever |
title_short | Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever |
title_sort | evaluation of the efficacy of doxycycline, ciprofloxacin, levofloxacin, and co-trimoxazole using in vitro and in vivo models of q fever |
topic | Experimental Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522727/ https://www.ncbi.nlm.nih.gov/pubmed/34370577 http://dx.doi.org/10.1128/AAC.00673-21 |
work_keys_str_mv | AT clayka evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever AT hartleymg evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever AT armstrongs evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever AT bewleykr evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever AT godwink evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever AT raynere evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever AT vipondj evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever AT baileym evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever AT atkinstp evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever AT norvilleih evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever |